{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:15:00Z","timestamp":1794035700712,"version":"4.8.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:00:00Z","timestamp":1654300800000},"content-version":"am","delay-in-days":338,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.bcp.2021.114432","type":"journal-article","created":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T18:03:37Z","timestamp":1611684217000},"page":"114432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":485,"special_numbering":"C","title":["The growth of siRNA-based therapeutics: Updated clinical studies"],"prefix":"10.1016","volume":"189","author":[{"given":"M. May","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raman","family":"Bahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore P.","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 E.","family":"Manautou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-bo","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bcp.2021.114432_b0005","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2144\/000112792","article-title":"RNAi mechanisms and applications","volume":"44","author":"Kim","year":"2008","journal-title":"Biotechniques"},{"key":"10.1016\/j.bcp.2021.114432_b0010","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.addr.2015.01.007","article-title":"Preclinical and clinical development of siRNA-based therapeutics","volume":"87","author":"Ozcan","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6669","key":"10.1016\/j.bcp.2021.114432_b0015","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bcp.2021.114432_b0020","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.bcp.2021.114432_b0025","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1101\/gr.146175.112","article-title":"Decoding the human genome","volume":"22","author":"Frazer","year":"2012","journal-title":"Genome Res."},{"issue":"7","key":"10.1016\/j.bcp.2021.114432_b0030","doi-asserted-by":"crossref","first-page":"e3097","DOI":"10.1002\/jgm.3097","article-title":"Clinical advances of siRNA therapeutics","volume":"21","author":"Hu","year":"2019","journal-title":"J. Gene Med."},{"issue":"10","key":"10.1016\/j.bcp.2021.114432_b0035","first-page":"570","article-title":"FDA approves patisiran to treat hereditary transthyretin amyloidosis","volume":"14","author":"Wood","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.bcp.2021.114432_b0040","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","article-title":"Givosiran: first approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.bcp.2021.114432_b0045","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s11095-017-2134-2","article-title":"The race of 10 synthetic RNAi-based drugs to the pharmaceutical market","volume":"34","author":"Titze-de-Almeida","year":"2017","journal-title":"Pharm. Res."},{"issue":"20","key":"10.1016\/j.bcp.2021.114432_b0050","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1101\/gad.927801","article-title":"Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans","volume":"15","author":"Ketting","year":"2001","journal-title":"Genes Dev."},{"issue":"1","key":"10.1016\/j.bcp.2021.114432_b0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0092-8674(00)80620-0","article-title":"RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals","volume":"101","author":"Zamore","year":"2000","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.bcp.2021.114432_b0060","doi-asserted-by":"crossref","first-page":"48","DOI":"10.59566\/IJBS.2017.13048","article-title":"Molecular mechanisms and biological functions of siRNA","volume":"13","author":"Dana","year":"2017","journal-title":"Int. J. Biomed. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2021.114432_b0065","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt.3802","article-title":"Overcoming cellular barriers for RNA therapeutics","volume":"35","author":"Dowdy","year":"2017","journal-title":"Nat. Biotechnol."},{"issue":"7","key":"10.1016\/j.bcp.2021.114432_b0070","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/mt.2009.91","article-title":"The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice","volume":"17","author":"Gao","year":"2009","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.bcp.2021.114432_b0075","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.bcp.2021.114432_b0080","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3390\/molecules22101724","article-title":"Enhancing the therapeutic delivery of oligonucleotides by chemical modification and nanoparticle encapsulation","volume":"22","author":"Sun","year":"2017","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.bcp.2021.114432_b0085","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1208\/s12248-010-9210-4","article-title":"Delivery of siRNA therapeutics: barriers and carriers","volume":"12","author":"Wang","year":"2010","journal-title":"AAPS J."},{"issue":"4","key":"10.1016\/j.bcp.2021.114432_b0090","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.bcp.2021.114432_b0095","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15300-1","article-title":"Imaging small molecule-induced endosomal escape of siRNA","volume":"11","author":"Du Rietz","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2021.114432_b0100","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3389\/fimmu.2017.00331","article-title":"RNA interference-induced innate immunity, off-target effect, or immune adjuvant?","volume":"8","author":"Meng","year":"2017","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.bcp.2021.114432_b0105","doi-asserted-by":"crossref","first-page":"828","DOI":"10.4161\/rna.20206","article-title":"RNA mediated Toll-like receptor stimulation in health and disease","volume":"9","author":"Dalpke","year":"2012","journal-title":"RNA Biol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114432_b0110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"issue":"10","key":"10.1016\/j.bcp.2021.114432_b0115","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2174\/0929867013372391","article-title":"Backbone modification of nucleic acids: synthesis, structure and therapeutic applications","volume":"8","author":"Micklefield","year":"2001","journal-title":"Curr. Med. Chem."},{"issue":"17","key":"10.1016\/j.bcp.2021.114432_b0120","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1002\/cbic.201600265","article-title":"Stereospecific effects of oxygen-to-sulfur substitution in DNA phosphate on ion pair dynamics and protein-DNA affinity","volume":"17","author":"Nguyen","year":"2016","journal-title":"ChemBioChem"},{"issue":"3","key":"10.1016\/j.bcp.2021.114432_b0125","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1172\/JCI125228","article-title":"Selective tissue targeting of synthetic nucleic acid drugs","volume":"129","author":"Seth","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.bcp.2021.114432_b0130","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1261\/rna.5103703","article-title":"siRNA function in RNAi: a chemical modification analysis","volume":"9","author":"Chiu","year":"2003","journal-title":"RNA"},{"key":"10.1016\/j.bcp.2021.114432_b0135","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3389\/fphar.2019.00444","article-title":"Current development of siRNA bioconjugates: from research to the clinic","volume":"10","author":"Chernikov","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114432_b0140","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1038\/mtna.2015.23","article-title":"siRNA Versus miRNA as therapeutics for gene silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"13","key":"10.1016\/j.bcp.2021.114432_b0145","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1021\/jm050044o","article-title":"Positional effect of chemical modifications on short interference RNA activity in mammalian cells","volume":"48","author":"Prakash","year":"2005","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2021.114432_b0150","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biotechadv.2019.04.012","article-title":"RNAi therapeutic and its innovative biotechnological evolution","volume":"37","author":"Weng","year":"2019","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.bcp.2021.114432_b0155","article-title":"Pharmacokinetics of patisiran, the first approved RNA interference therapy in patients with hereditary transthyretin-mediated amyloidosis","author":"Zhang","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114432_b0160","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40824-019-0166-x","article-title":"Therapeutic efficacy of nanoparticles and routes of administration","volume":"23","author":"Chenthamara","year":"2019","journal-title":"Biomater. Res."},{"issue":"8","key":"10.1016\/j.bcp.2021.114432_b0165","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22081356","article-title":"Synthesis of 5'-GalNAc-conjugated oligonucleotides: a comparison of solid and solution-phase conjugation strategies","volume":"22","author":"Cedillo","year":"2017","journal-title":"Molecules"},{"issue":"13","key":"10.1016\/j.bcp.2021.114432_b0170","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.bcp.2021.114432_b0175","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther."},{"issue":"1","key":"10.1016\/j.bcp.2021.114432_b0180","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40291-019-00438-6","article-title":"Leading RNA interference therapeutics part 2: silencing delta-aminolevulinic acid synthase 1, with a focus on givosiran","volume":"24","author":"de Paula Brandao","year":"2020","journal-title":"Mol. Diagn. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2021.114432_b0185","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/med.21479","article-title":"Chemical modifications of nucleic acid drugs and their delivery systems for gene-based therapy","volume":"38","author":"Chen","year":"2018","journal-title":"Med. Res. Rev."},{"issue":"15","key":"10.1016\/j.bcp.2021.114432_b0190","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","article-title":"Patisiran: first global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2021.114432_b0195","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/TACG.S19903","article-title":"Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis","volume":"5","author":"Hund","year":"2012","journal-title":"Appl. Clin. Genet."},{"issue":"8","key":"10.1016\/j.bcp.2021.114432_b0200","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1212\/WNL.0000000000001870","article-title":"Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study","volume":"85","author":"Adams","year":"2015","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.bcp.2021.114432_b0205","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","article-title":"Evolving landscape in the management of transthyretin amyloidosis","volume":"47","author":"Hawkins","year":"2015","journal-title":"Ann. Med."},{"issue":"2","key":"10.1016\/j.bcp.2021.114432_b0210","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/13506129.2016.1160882","article-title":"Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis","volume":"23","author":"Butler","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.bcp.2021.114432_b0215","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.bcp.2021.114432_b0220","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12883-017-0948-5","article-title":"Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy","volume":"17","author":"Adams","year":"2017","journal-title":"BMC Neurol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114432_b0225","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bcp.2021.114432_b0230","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/jamacardio.2019.0849","article-title":"Association of patisiran, an RNA interference therapeutic, with regional left ventricular myocardial strain in hereditary transthyretin amyloidosis: the APOLLO study","volume":"4","author":"Minamisawa","year":"2019","journal-title":"JAMA Cardiol."},{"issue":"4","key":"10.1016\/j.bcp.2021.114432_b0235","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.bcp.2021.114432_b0240","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/13506129.2020.1730790","article-title":"Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis","volume":"27","author":"Obici","year":"2020","journal-title":"Amyloid"},{"issue":"3","key":"10.1016\/j.bcp.2021.114432_b0245","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00415-019-09602-8","article-title":"Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis","volume":"267","author":"Gonz\u00e1lez-Duarte","year":"2020","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114432_b0250","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13023-020-01399-4","article-title":"A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis","volume":"15","author":"Coelho","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"issue":"9","key":"10.1016\/j.bcp.2021.114432_b0255","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2021.114432_b0260","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/nmt-2018-0033","article-title":"Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis","volume":"9","author":"Kristen","year":"2019","journal-title":"Neurodegener Dis. Manage."},{"key":"10.1016\/j.bcp.2021.114432_b0265","unstructured":"S.D. Whatley, M.N. Badminton, GeneReviews((R)), M.P. Adam, et al. Acute Intermittent Porphyria 1993 Seattle (WA)."},{"issue":"3","key":"10.1016\/j.bcp.2021.114432_b0270","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ymgme.2019.07.002","article-title":"Acute hepatic porphyrias: current diagnosis & management","volume":"128","author":"Anderson","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.bcp.2021.114432_b0275","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3390\/metabo4040977","article-title":"Clinically important features of porphyrin and heme metabolism and the porphyrias","volume":"4","author":"Besur","year":"2014","journal-title":"Metabolites"},{"key":"10.1016\/j.bcp.2021.114432_b0280","doi-asserted-by":"crossref","unstructured":"N. Pallet et al. Porphyria and kidney diseases 11(2) 2018 191-197.","DOI":"10.1093\/ckj\/sfx146"},{"issue":"1","key":"10.1016\/j.bcp.2021.114432_b0285","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/cpt.1802","article-title":"Pharmacokinetics and pharmacodynamics of the small interfering ribonucleic acid, givosiran, in patients with acute hepatic porphyria","volume":"108","author":"Agarwal","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2021.114432_b0290","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa1807838","article-title":"Phase 1 trial of an RNA interference therapy for acute intermittent porphyria","volume":"380","author":"Sardh","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.bcp.2021.114432_b0295","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.bcp.2021.114432_b0300","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJMe2010986","article-title":"Givosiran - running RNA interference to fight porphyria attacks","volume":"382","author":"Gonzalez-Aseguinolaza","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2021.114432_b0305","doi-asserted-by":"crossref","DOI":"10.1007\/s40265-020-01463-0","article-title":"Lumasiran: first approval","author":"Scott","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2021.114432_b0310","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/864580","article-title":"Primary hyperoxaluria","volume":"2011","author":"Harambat","year":"2011","journal-title":"Int. J. Nephrol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114432_b0315","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00240-018-1089-z","article-title":"Molecular basis of primary hyperoxaluria: clues to innovative treatments","volume":"47","author":"Dindo","year":"2019","journal-title":"Urolithiasis"},{"issue":"7","key":"10.1016\/j.bcp.2021.114432_b0320","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1021\/acs.bioconjchem.0c00268","article-title":"Investigational therapies for primary hyperoxaluria","volume":"31","author":"Kletzmayr","year":"2020","journal-title":"Bioconjug. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2021.114432_b0325","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1177\/0192623318792537","article-title":"The nonclinical safety profile of GalNAc-conjugated RNAi therapeutics in subacute studies","volume":"46","author":"Janas","year":"2018","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.bcp.2021.114432_b0330","doi-asserted-by":"crossref","unstructured":"M.M. Janas et al., Safety evaluation of 2'-deoxy-2'-fluoro nucleotides in GalNAc-siRNA conjugates. Nucleic Acids Res, 2019. 47(7): p. 3306-3320.","DOI":"10.1093\/nar\/gkz140"},{"issue":"3","key":"10.1016\/j.bcp.2021.114432_b0335","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","article-title":"Advanced siRNA designs further improve in vivo performance of GalNAc-siRNA conjugates","volume":"26","author":"Foster","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcp.2021.114432_b0340","article-title":"Single dose pharmacokinetics and pharmacodynamics of transthyretin targeting GalNAc-siRNA conjugate, vutrisiran, in healthy subjects","author":"Habtemariam","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.bcp.2021.114432_b0345","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.ymthe.2018.05.016","article-title":"Specific inhibition of hepatic lactate dehydrogenase reduces oxalate production in mouse models of primary hyperoxaluria","volume":"26","author":"Lai","year":"2018","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2021.114432_b0350","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11883-012-0291-7","article-title":"How do we improve patient compliance and adherence to long-term statin therapy?","volume":"15","author":"Maningat","year":"2013","journal-title":"Curr. Atheroscler. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2021.114432_b0355","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacl.2019.11.001","article-title":"Inclisiran-new hope in the management of lipid disorders?","volume":"14","author":"Dyrbus","year":"2020","journal-title":"J. Clin. Lipidol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114432_b0360","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1056\/NEJMp1614154","article-title":"Oligonucleotide therapeutics - a new class of cholesterol-lowering drugs","volume":"376","author":"Khvorova","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2021.114432_b0365","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.bcp.2021.114432_b0370","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1161\/CIRCULATIONAHA.119.044431","article-title":"Inclisiran durably lowers low-density lipoprotein cholesterol and proprotein convertase subtilisin\/kexin type 9 expression in homozygous familial hypercholesterolemia: the ORION-2 pilot study","volume":"141","author":"Hovingh","year":"2020","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.bcp.2021.114432_b0375","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.bcp.2021.114432_b0380","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.bcp.2021.114432_b0385","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/s41587-019-0351-4","article-title":"PCSK9-gene-silencing, cholesterol-lowering drug impresses","volume":"37","author":"Sheridan","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcp.2021.114432_b0390","article-title":"Do PCSK9 inhibitors do anything more than reduce LDL cholesterol?","volume":"368","author":"Bamji","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.bcp.2021.114432_b0395","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.amjcard.2020.05.024","article-title":"A meta-analysis of cardiovascular outcomes in patients with hypercholesterolemia treated with inclisiran","volume":"128","author":"Asbeutah","year":"2020","journal-title":"Am. J. Cardiol."},{"issue":"9","key":"10.1016\/j.bcp.2021.114432_b0400","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2019.221093","article-title":"Hemophilia A and B: molecular and clinical similarities and differences","volume":"104","author":"Castaman","year":"2019","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.bcp.2021.114432_b0405","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/MBC.0000000000000225","article-title":"Rationale for individualizing haemophilia care","volume":"26","author":"S\u00f8rensen","year":"2015","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.bcp.2021.114432_b0410","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/JBM.S159297","article-title":"An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B","volume":"9","author":"Machin","year":"2018","journal-title":"J. Blood Med."},{"issue":"5","key":"10.1016\/j.bcp.2021.114432_b0415","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2021.114432_b0420","doi-asserted-by":"crossref","unstructured":"C. Berk et al., Pharmacodynamic and Pharmacokinetic Properties of Full Phosphorothioate Small Interfering RNAs for Gene Silencing In Vivo. Nucleic Acid Ther, 2020.","DOI":"10.1089\/nat.2020.0852"},{"issue":"9","key":"10.1016\/j.bcp.2021.114432_b0425","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of antithrombin in hemophilia A or B with RNAi therapy","volume":"377","author":"Pasi","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bcp.2021.114432_b0430","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrg2968","article-title":"Current prospects for RNA interference-based therapies","volume":"12","author":"Davidson","year":"2011","journal-title":"Nat. Rev. Genet."},{"issue":"2","key":"10.1016\/j.bcp.2021.114432_b0435","first-page":"85","article-title":"Acute kidney injury: definition, pathophysiology and clinical phenotypes","volume":"37","author":"Makris","year":"2016","journal-title":"Clin. Biochem. Rev."},{"issue":"8","key":"10.1016\/j.bcp.2021.114432_b0440","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s40265-019-01119-8","article-title":"Drugs in development for acute kidney injury","volume":"79","author":"Hulse","year":"2019","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.bcp.2021.114432_b0445","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/13543784.2017.1274730","article-title":"Recent early clinical drug development for acute kidney injury","volume":"26","author":"Gallagher","year":"2017","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"4","key":"10.1016\/j.bcp.2021.114432_b0450","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1089\/nat.2012.0371","article-title":"Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration","volume":"22","author":"Thompson","year":"2012","journal-title":"Nucleic Acid Ther."},{"issue":"8","key":"10.1016\/j.bcp.2021.114432_b0455","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1681\/ASN.2008111204","article-title":"siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury","volume":"20","author":"Molitoris","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.bcp.2021.114432_b0460","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/ICU.0000000000000318","article-title":"The enigma of nonarteritic anterior ischemic optic neuropathy: an update for the comprehensive ophthalmologist","volume":"27","author":"Gaier","year":"2016","journal-title":"Curr. Opin. Ophthalmol."},{"issue":"6","key":"10.1016\/j.bcp.2021.114432_b0465","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1038\/cddis.2011.54","article-title":"Ocular neuroprotection by siRNA targeting caspase-2","volume":"2","author":"Ahmed","year":"2011","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.bcp.2021.114432_b0470","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1089\/nat.2014.0489","article-title":"Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection","volume":"24","author":"Solano","year":"2014","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.bcp.2021.114432_b0475","doi-asserted-by":"crossref","unstructured":"J. Jiang et al., Progress on ocular siRNA gene-silencing therapy and drug delivery systems. Fundam Clin Pharmacol, 2020.","DOI":"10.1111\/fcp.12561"},{"issue":"3","key":"10.1016\/j.bcp.2021.114432_b0480","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/WNO.0000000000000409","article-title":"A nonarteritic anterior ischemic optic neuropathy clinical trial: an industry and NORDIC collaboration","volume":"36","author":"Kupersmith","year":"2016","journal-title":"J. Neuroophthalmol."},{"issue":"2","key":"10.1016\/j.bcp.2021.114432_b0485","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/bjophthalmol-2019-314656","article-title":"Controversies on neuroprotection therapy in non-arteritic anterior ischaemic optic neuropathy","volume":"104","author":"Hayreh","year":"2020","journal-title":"Br. J. Ophthalmol."},{"issue":"14","key":"10.1016\/j.bcp.2021.114432_b0490","doi-asserted-by":"crossref","first-page":"DES7","DOI":"10.1167\/iovs.17-23475","article-title":"Definition and diagnostic criteria of dry eye disease: historical overview and future directions","volume":"59","author":"Shimazaki","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2021.114432_b0495","doi-asserted-by":"crossref","first-page":"309","DOI":"10.4274\/tjo.69320","article-title":"Current management and treatment of dry eye disease","volume":"48","author":"\u015eim\u015fek","year":"2018","journal-title":"Turk. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.bcp.2021.114432_b0500","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/13543784.2018.1457647","article-title":"Tivanisiran, a novel siRNA for the treatment of dry eye disease","volume":"27","author":"Moreno-Monta\u00f1\u00e9s","year":"2018","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"8","key":"10.1016\/j.bcp.2021.114432_b0505","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1167\/iovs.18-24304","article-title":"TRPV1 and TRPM8 channels and nocifensive behavior in a rat model for dry eye","volume":"59","author":"Bereiter","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2021.114432_b0510","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1089\/jop.1997.13.41","article-title":"Penetration into the anterior chamber via the conjunctival\/scleral pathway","volume":"13","author":"Schoenwald","year":"1997","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"14","key":"10.1016\/j.bcp.2021.114432_b0515","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.1167\/iovs.16-20303","article-title":"Safety and efficacy clinical trials for SYL1001, a novel short interfering RNA for the treatment of dry eye disease","volume":"57","author":"Benitez-Del-Castillo","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.bcp.2021.114432_b0520","doi-asserted-by":"crossref","unstructured":"Second RNAi drug approved. Nat Biotechnol, 2020. 38(4): p. 385.","DOI":"10.1038\/s41587-020-0494-3"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221000289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221000289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:22:07Z","timestamp":1757769727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295221000289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":104,"alternative-id":["S0006295221000289"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114432","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The growth of siRNA-based therapeutics: Updated clinical studies","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114432","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114432"}}